- Home
- RETO vs APRE Comparison
RETO vs APRE Comparison
Compare RETO & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RETO | APRE |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.9M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RETO | APRE |
|---|---|---|
| Price | $2.61 | $0.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 436.5K | 71.8K |
| Earning Date | 05-05-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,109,956.00 | $488,239.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16864.81 | N/A |
| 52 Week Low | $1.77 | $0.90 |
| 52 Week High | $61.50 | $5.00 |
Technical Indicators
Market Signals| Indicator | RETO | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 30.35 |
| Support Level | $1.77 | $0.90 |
| Resistance Level | $3.54 | $1.14 |
| Average True Range (ATR) | 0.57 | 0.09 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 24.57 | 6.54 |
Price Performance
Historical ComparisonAbout RETO ReTo Eco-Solutions Inc.
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Machinery and Equipment sales, and Technology Consulting and other services. The company earns its revenue from the Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.